To Evaluate the Efficacy and Safety of HL151 Versus Placebo in Perennial Allergic Rhinitis Patients

4week, a Multicenter, Randomized, Double-blinded, Parallel, Therapeutic confirmatory Clinical Trial to Evaluate the Efficacy and Safety of HL151 versus Placebo in perennial allergic rhinitis patients

Inclusion criteria

• Both gender, 19 years ≤ age
• At least two years history of allergic rhinitis prior to participate in clinical trial
• Patients with positive reaction for perennial allergen in tests(prick test or Intradermal test or MAST(Multiple Allergen Simultaneous Test) or Immuno CAP test) within 12 months
• In visit 2, patients with over mean 5 points of the total reflective TNSS score per day (during the run-in period) (highest value 12 points)
• Patients who can ability to record subject diary
• Patients who agreed to maintain the same environment throughout the entire clinical trial period.
• Written consent voluntarily to participate in this clinical trial after understanding and detailed explanation about this clinical trial

Exclusion criteria

• Patients with non-allergic rhinitis
• Patients with asthma due to the following diseases(but patients with mild and intermittent asthma are available to participate in clinical trials)

• Within four weeks from the date of screening, patients who visit the emergency room or have been hospitalized within 12 weeks or
• patients with asthma who need other treatment except short-acting Beta-efficient respiratory relaxants Inhalation
• Patients with obstructive nasal polyp or severe deviated nasal septum
• Patients who Within 12 weeks from the date of screening, had damage or surgery around nasal cavity
• Patients with anamnesis in acute /chronic sinusitis